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SUMMARY Respiratory viral infections are associated with a wide range of acute 
syndromes and infectious disease processes in children and adults worldwide. Many 
viruses are implicated in these infections, and these viruses are spread largely via re-
spiratory means between humans but also occasionally from animals to humans. 
This article is an American Society for Microbiology (ASM)-sponsored Practical Guid-
ance for Clinical Microbiology (PGCM) document identifying best practices for diag-
nosis and characterization of viruses that cause acute respiratory infections and re-
places the most recent prior version of the ASM-sponsored Cumitech 21 document, 
Laboratory Diagnosis of Viral Respiratory Disease, published in 1986. The scope of the
original document was quite broad, with an emphasis on clinical diagnosis of a wide 
variety of infectious agents and laboratory focus on antigen detection and viral cul-
ture. The new PGCM document is designed to be used by laboratorians in a wide 
variety of diagnostic and public health microbiology/virology laboratory settings 
worldwide. The article provides guidance to a rapidly changing field of diagnostics 
and outlines the epidemiology and clinical impact of acute respiratory viral infec-
tions, including preferred methods of specimen collection and current methods for 
diagnosis and characterization of viral pathogens causing acute respiratory tract in-
fections. Compared to the case in 1986, molecular techniques are now the preferred 
diagnostic approaches for the detection of acute respiratory viruses, and they allow 
for automation, high-throughput workflows, and near-patient testing. These changes 
require quality assurance programs to prevent laboratory contamination as well as 
strong preanalytical screening approaches to utilize laboratory resources appropri-
ately. Appropriate guidance from laboratorians to stakeholders will allow for appro-
priate specimen collection, as well as correct test ordering that will quickly identify 
highly transmissible emerging pathogens.
KEYWORDS clinical, guidance, laboratory, respiratory, virus
INTRODUCTION
Background
The most recent version of the American Society for Microbiology (ASM)-sponsored 
Cumitech 21 document, Laboratory Diagnosis of Viral Respiratory Disease, was published 
in 1986 (1). The scope of the original document was quite broad, with an emphasis on 
clinical diagnosis of a wide variety of infectious agents and laboratory focus on antigen 
detection and viral culture. The date of publication of the most recent Cumitech 
document was roughly 3 years after Kary Mullis’ initial work on PCR technology. Since 
that time, the practice of clinical microbiology has significantly changed, most notably 
with the development of molecular approaches that have increasingly replaced tradi-
tional methods for diagnosis of respiratory viruses. Specimen collection techniques 
have likewise improved and have enhanced the predictive values of these new mo-
lecular methods. Development of electronic order entry systems, computerized labo-
ratory information systems, and automated reporting has reduced turnaround times 
(TATs) for laboratory results dramatically even in environments where laboratory 
centralization has occurred. The continual emergence of new respiratory pathogens 
requires laboratorians to recognize laboratory testing limitations and understand when 
and how to refer suspicious cases to public health reference laboratories.
Purpose
This document is an ASM-sponsored Practical Guidance for Clinical Microbiology 
(PGCM) identifying best practices for diagnosis and characterization of viruses that 
cause acute respiratory infections (ARIs). The document is designed to be used by 
laboratorians in a wide variety of diagnostic and public health microbiology/virology 
laboratory settings, especially by members of the ASM worldwide. As such, this 
consensus document is structured to cover a wide range of practice settings, and to 
reflect changes in available technology, clinical practice, and viral pathogens since 
1986. The document outlines the epidemiology and clinical impact of acute respiratory 
viral infections, including preferred methods of specimen collection and current meth-
ods for diagnosis and characterization of viral pathogens causing acute respiratory tract 
infections. Laboratory-developed and commercial diagnostic tools, approaches for 
diagnosis of emerging pathogens, and detection of antiviral resistance in influenza A 
virus (FLUA) and influenza A virus (FLUB) infections are also discussed. Specimen 
handling approaches for specimens from multiple body sites, such as nasopharyngeal 
swabs (NPS), nasopharyngeal aspirates (NPA), nasal swabs (NS), nasal washes (NW), 
oropharyngeal and throat swabs (OPS/TS), sputa, bronchoalveolar lavage (BAL) fluids, 
bronchoalveolar washes (BAW), and other lower respiratory tract specimens, are cov-
ered. Given the changes in turnaround time for these newer technologies and increases 
in clinical use, the document also addresses appropriate laboratory utilization of 
diagnostic respiratory viral testing. The scope of the document has shifted since the last 
version of the Cumitech, which included discussion on clinical overlap of viral patho-
gens causing acute respiratory tract infections as well as other pathogens that were 
shown to infect the respiratory tract, such as atypical bacterial pathogens. The current 
document focuses strictly on viruses that primarily cause acute respiratory infections, 
related syndromes, or disease processes. Viruses that can infect or shed from the 
respiratory tract but lead chiefly to other presentations such as rash, vesicles, parotitis, 
gastroenteritis, or mononucleosis-like syndromes (herpes simplex virus, varicella zoster 
virus, cytomegalovirus, Epstein-Barr virus, parvovirus B19, measles virus, rubella virus, 
mumps virus, bocavirus, and hantavirus) are not discussed in this document.
The primary focus of this document is pathogens with well-documented causal 
effects for acute respiratory infections, namely influenza A virus (FLUA), influenza B virus 
(FLUB), respiratory syncytial viruses (RSVs) A and B, respiratory enteroviruses (EVs), 
rhinoviruses (RVs), respiratory adenoviruses (ADVs), human metapneumovirus (hMPV), 
parainfluenza viruses (PIVs) 1 to 4, and coronaviruses (CoVs) (NL63, OC43, HKU-1, and 
229E). The document also discusses the diagnosis and characterization of emerging 
respiratory viral pathogens, including CoVs (causing Middle Eastern respiratory syn-
drome [MERS] and severe acute respiratory syndrome [SARS]) and novel FLU strains 
arising from swine and avian sources.
EPIDEMIOLOGY AND CLINICAL PRESENTATION OF ACUTE RESPIRATORY VIRAL 
INFECTIONS
Circulation of Respiratory Viruses: a Global Problem
The increased capacity for molecular diagnostics worldwide has enhanced our 
understanding of global circulation patterns of respiratory viruses (2). From the clinical 
laboratory perspective, understanding the circulation patterns of viruses will influence 
the predictive value of respiratory virus testing and potentially the interpretation of 
respiratory virus test results based on pretest probability (3). A number of geographic 
regions now have well-established surveillance systems for FLU and occasionally other 
respiratory viruses associated with acute illness (4–7). A complicated global viral 
circulation pattern shows that some viruses maintain consistent seasonality, while 
others vary extensively. In the Northern Hemisphere, RV and respiratory EVs typically 
circulate in the late summer and early fall (autumn), while FLUA predictably peaks in 
December or January (Fig. 1). PIV types, however, have varied circulation patterns with 
seasonality depending on the subtype, and dominant types can change from year to 
year (8). Although we can begin to predict patterns of respiratory virus circulation as 
surveillance and detection capacities improve (9), viruses may be identified outside 
their normal seasonal infection patterns due to patient activities, such as travel to 
regions where the virus is currently circulating (10). Knowing the travel history com-
bined with active pathogen surveillance (e.g., identifying a patient who presents during 
a North American summer with acute respiratory infection after travel to the Southern 
Hemisphere where FLU or RSV is circulating) can help direct appropriate infection 
prevention and control measures, as not all respiratory viruses require the same level 
of patient isolation (11, 12).
Acute respiratory infections. Acute respiratory infections (ARIs) are among the most 
common infections reported worldwide. In the 2013 global disease burden study 
sponsored by the World Health Organization, respiratory infections were listed as the 
leading cause of infectious disease and as being responsible for approximately 120 
million disability-adjusted life years (DALYs) (a measure of the disease burden and its 
impact on quality of life) (13). Lower respiratory tract infections (LRTIs) accounted for 
greater than 90% of all DALYs, with approximately 35% of cases occurring in children 
less than 5 years old (13, 14). The impact of respiratory infections on human health is 
reflected in the large number of hospital and emergency room visits for both adults and 
children (e.g., in the United States, there are 140,000 to 710,000 FLU-related hospital-
izations per year), where respiratory viral infection is the most common reason to seek
medical care (15, 16).
FIG 1 Circulation of common respiratory viruses in a large geographic area within the Northern Hemisphere. The data
represent all acute respiratory virus testing for multiple years in a population of 4.1 million patients, using a common testing
algorithm. The seasonality of viruses varies. (Generated by S. J. Drews and the ProvLab Alberta Laboratory Surveillance and
Informatics Team, 2016.)
Mechanisms of transmission. Respiratory viruses are transmitted primarily through 
two mechanisms: (i) inhalation of infectious droplets and (ii) contact with contaminated 
fomites. Aerosol transmission is the most common route of infection. Large (10 to 
100 m in diameter) aerosolized droplets can transmit viruses from the index case to 
a new host in close proximity (0.9 m), while small (10 m in diameter) aerosolized 
droplets, produced during coughing or sneezing or through aerosol-generating pro-
cedures, can carry viral particles to new hosts several meters away (1.8 m). Transmis-
sion via fomites from self-inoculation of the respiratory tract mucosa is the second most 
common route of infection (17) (Table 1). Survivability and infectivity of viruses on 
surfaces may vary from hours to days and depend on a number of viral and nonviral 
factors. Nonenveloped viruses are more likely to cause infection via direct contact, as 
they are more stable in the environment than enveloped viruses and are therefore 
more likely to survive for extended periods outside the host (18). Animal and climato-
logical model systems suggest that respiratory virus (e.g., FLUA) transmission may also 
be enhanced under specific environmental conditions, such as low temperature and 
low humidity (19–21). It is important for laboratorians and clinicians to be aware of 
likely transmission routes used by respiratory viruses in order to implement adequate 
infection control practices, select appropriate specimen types, and safely perform 
laboratory manipulations (Table 1) (22).
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Close contact in living environments such as long-term care facilities facilitate 
transmission to the elderly, who are often at higher risk for severe outcomes from 
respiratory virus infections, such as pneumonia, acute-care hospitalization, and death. 
In addition, illness may also occur in staff members. Challenges may arise because these 
environments are not thought of as primary health care environments and may not 
have infection control protocols that are as stringent as those in health care settings 
(23, 24).
Similarly, pediatric day care settings are another transmission setting for exposure to 
multiple respiratory viruses. A prospective cohort study from Washington State iden-
tified RSV, ADV, and RV as leading pathogens, with hMPV and CoV being less frequent, 
in children in day care settings (25), and air sampling experiments have identified RSV 
these settings (26). Children attending day care are at increased risk for respiratory 
infections (all etiologies), especially at the start of entry into day care (27), and can be 
a potential source of RSV infection for premature infants, who are at high risk of severe 
compilations and outcomes (28).
Acute respiratory viral infections. There is significant overlap in clinical symptoms 
associated with the different viruses causing respiratory illnesses (Table 2). The U.S. 
Centers for Disease Control and Prevention (CDC) has established influenza-like illness 
(ILI) criteria used for epidemiological surveillance to identify patients with likely influ-
enza infection (29, 30). These clinical criteria include cough, fever (temperature greater 
than or equal to 100°F [37.8°C]), and/or sore throat and no identifiable cause other than 
influenza (31); however, the specificity of these criteria is poor, as many other patients 
with noninfluenza respiratory viruses can present similarly (32). In many cases, acute 
respiratory infection (ARI) due to these viruses is indistinguishable from illness due to 
bacteria on the basis of clinical presentation alone. Table 2 provides examples of 
diseases and disorders that are caused by respiratory viral infection; however, this table 
does not exclude the possibility that an unlisted virus may be the causative agent of a 
disease or disorder.
(i) The host. The host response to viral infections relies on elements of both the 
innate immunity and the adaptive immunity. Epithelial cells covering the mucosal 
surface of the airway constitute the first physical barrier encountered by respiratory 
viruses. Here, tight junctions connect the cells and provide a sealed environment, 
preventing viral movement outside the respiratory tract. A layer of mucus overlays the 
epithelial surface, and an upward directional movement of cilia effectively traps and 
clears virus particles from the airway epithelium (33, 34). Binding and phagocytosis of 
viruses result in production of several proinflammatory molecules, including interleu-
kins (e.g., interleukin-1 [IL-1] and IL-18), / defensins, collectins, type I interferons 
alpha/beta, and immunoglobulin A (IgA), and attract natural killer cells. Upregulation of 
this innate immune response limits local spread of the respiratory viruses (34) and 
serves as the front-line defense prior to activation of the adaptive immune system.
In infants, the immune system is still developing. The lack of complete immune 
memory, reduced innate and adaptive immunity, and physiological differences in 
airways compared to those in adults (35) increase the susceptibility to viral infections 
and disease severity (36). The immune response to respiratory viral infections may be 
augmented by protective effects of passive antibodies transmitted in utero (37) and 
other factors, including breastfeeding (38, 39). Reinfections with the same virus are not 
uncommon, and disease severity as well as patient outcomes is dependent on multiple 
factors, including viral genetic diversity and intrinsic/extrinsic patient factors (34, 
40–42).
Individuals at increased risk for complications due to respiratory virus infections 
include children, older adults (65 years old), patients with underlying respiratory 
conditions, and those with suppressed immune functions (e.g., transplant patients). In 
patients with underlying respiratory conditions (e.g., chronic bronchitis, chronic ob-
structive asthma, chronic obstructive pulmonary disease [COPD], or emphysema), a 
decrease (mucostasis) or increase (mucus hypersecretion) in the mucociliary escalator 
function may lead to decreased clearance of viral pathogens and increased risk of
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infection (33). In older adults, increased susceptibility to viral infections, age-dependent 
vaccine effectiveness (43) and more severe disease have been attributed to waning 
innate and adaptive immunity. Particularly, infection with RSV has been attributed to a 
decrease in memory CD8 T-cell function (44, 45). Similarly, immunosuppressed pa-
tients with profound and prolonged reduction in T-cell immunity are at increased risk 
for severe disease from viral infection (particularly ADV, hMPV, PIV, and RSV infections)
(46, 47). A few studies have suggested that genetic polymorphisms of innate immune 
effectors, such as Toll-like receptors (e.g., TLR-4), are associated with increased suscep-
tibility to severe respiratory viral infection (48, 49).
(ii) Environmental factors. Environmental factors may also influence the inci-
dence of disease caused by respiratory viral infection either alone or with other 
underlying factors such as asthma (50). These factors may include the number of 
siblings in family, environmental smoking exposure (51), air pollution, climatic 
conditions, or weather (52, 53).
(iii) Anatomic site of infection. As the name suggests, most acute upper respi-
ratory tract infections (URTIs) affect sites in the upper respiratory tract, including the 
larynx, nasal cavities, nasopharynx, oropharynx, throat, sinuses, conjunctiva, and 
inner ear, and commonly manifest as rhinosinusitis or the “common cold” (54), 
acute sinusitis (55, 56), acute laryngitis (57–59), conjunctivitis (54, 60–65), and otitis 
media (64, 66, 67). (Table 2).
Viruses in lower respiratory tract infections (LRTIs) affect deeper structures below the 
larynx, including the trachea, bronchus, and bronchoalveolar site, and manifest as 
bronchiolitis (68–71), bronchitis (72–76), and acute pneumonia (77–81).
Zoonotic viruses: human-animal health interfaces. The One Health concept is an 
integrative and collaborative approach that works to improve the health of humans 
and nonhuman animals while ensuring the protection of the natural environment (82). 
Clinicians and laboratorians should remain aware of the potential impact of One Health 
human-animal interfaces to allow for the emergence of new human respiratory viral 
pathogens (83, 84). Recent examples include human infection with the Middle East 
respiratory syndrome coronavirus (MERS-CoV) with camel exposure (83), swine variants 
of FLUA (84), pandemic FLU (pdm09), avian FLUA (e.g., H7N9) (85), and severe acute 
respiratory syndrome coronavirus (SARS-CoV) associated with bats and civet cats (86, 
87). Laboratorians should establish effective communication links with epidemiologists, 
clinicians, and animal health experts to understand the impact of zoonotic viruses on 
human illness (88). Identification of at-risk patients early by clinicians can reduce the 
potential for nosocomial transmission of zoonotic pathogens. From the laboratory 
perspective, this means following the epidemiology of emerging infections and com-
municating with clinicians and public health workers to assess risk and determine the 
testing required based on travel histories and animal exposures (89–91). These ap-
proaches not only will identify patients at risk and allow public health practitioners to 
implement strategies to reduce transmission and limit further exposure in health care 
facilities and the community but also will ensure that laboratories can work up 
specimens using appropriate biocontainment approaches to reduce the risk of labo-
ratory transmission of pathogens (92).
Section Summary and Recommendations
Respiratory viruses are a global problem with varied temporal and geographic 
patterns of circulation. Laboratorians and clinicians should understand that multiple 
viruses can cause similar signs and symptoms when infecting the upper or lower 
respiratory tract. Although some viruses may be more likely to be associated with some 
diseases, it is difficult to use clinical presentations alone to determine the causative 
agent. Laboratorians should have a firm understanding of viruses that are circulating in 
their region, as well as emerging infections in other regions of the world, as this 
information may guide clinicians and laboratorians in developing appropriate algo-
rithms to test for agents causing respiratory illness.
GUIDELINES ADDRESSING THE DIAGNOSIS AND MANAGEMENT OF SYNDROMES 
ASSOCIATED WITH ACUTE RESPIRATORY INFECTIONS
Laboratorians must consider how laboratory testing impacts the diagnosis and 
management (including infection control considerations, treatment, and prophylaxis) 
of patients presenting with ARIs so that they collaborate with their health care 
providers to develop effective utilization strategies and develop algorithms that prior-
itize of testing of patients for whom results can influence clinical decision making. The 
following section summarizes U.S. and international guidelines written in the English 
language for the diagnosis and management of respiratory virus infections. Although 
viral diagnosis does not typically affect the patient management of otherwise-healthy 
adult patients, these guidelines identify scenarios where respiratory virus testing has 
been identified to influence patient management.
Infectious Diseases Society of America
Community-acquired pneumonia. Together, the Infectious Diseases Society of 
America (IDSA) and the American Thoracic Society (ATS) published consensus guide-
lines for the management of community-acquired pneumonia in adults in 2007 (note 
that revisions of the ATS guidelines are in progress) (79). In the guidelines, they outline 
specific microbiological testing recommendations and discuss how to take an appro-
priate travel history to support the diagnosis of pneumonia. The document identifies 
respiratory viruses as an important cause of community-acquired pneumonia (CAP) in 
outpatients and inpatients and emphasizes the importance of testing for and public 
health reporting of emerging or novel virus strains. Improvements to diagnostic testing 
using molecular approaches are encouraged, and drawbacks to rapid antigen testing, 
including cost and false-negative and false-positive results, are discussed. The docu-
ment also provides support for use of antivirals (oseltamivir, zanamivir, or peramivir) in 
the treatment of seasonal and pandemic FLU, and it strongly supports vaccination in 
the prevention of seasonal influenza disease (79).
More recently (2011), the IDSA and the Pediatric Infectious Diseases Society (PIDS) 
published combined guidelines for the management of CAP in infants and children 
older than three months (93, 94). Since viral pathogens cause the majority of CAP in 
preschool-aged children, antibiotic therapy is not routinely required in this population. 
Testing for respiratory viral infections with a rapid, highly sensitive, and specific assay 
is recommended, as it may reduce the use of antibiotics in patients without clinical, 
laboratory, or radiological findings suggestive of bacterial coinfection. Antiviral therapy 
should be started as early as possible in children with moderate to severe CAP when 
FLU is circulating and symptoms are worsening. The group suggested that treatment 
not be delayed for laboratory confirmation, as negative laboratory tests (especially with 
rapid antigen testing) may not exclude disease. The American Academy of Pediatrics, in 
a policy statement by the Committee on Infectious Diseases and Bronchiolitis, did not 
recommend ribavirin for the treatment of RSV-CAP in infants. However, palivizumab 
prophylaxis of RSV was recommended by the American Academy of Pediatrics (94). The 
palivizumab guidelines have since been updated (95) and do not emphasize laboratory 
testing for RSV. No recommendations were provided for the use of antivirals against 
PIVs, ADVs, hMPVs, or CoVs in pediatric CAP.
FLU-specific guidance. In 2009, the IDSA released guidelines on the diagnosis, 
institutional outbreak management, chemoprophylaxis, and treatment of FLU in adults 
and children (96) (an update for this document is currently in process). Specific 
demographic criteria were outlined for whom should be tested for FLU, and testing was 
recommended only if results would influence clinical management. These situations 
partially include the following: immunocompetent outpatients with acute febrile respi-
ratory symptoms (within 5 days of onset) at high risk for hospitalization or death, 
immunocompromised outpatients with febrile respiratory symptoms (regardless of 
onset date), and immunocompetent and immunocompromised hospitalized patients 
with fever and respiratory symptoms, including CAP patients (regardless of onset date). 
FLU testing was also recommended for elderly and infant patients with fever of
unknown origin or sepsis (regardless of onset date), children presenting for medical 
care with fever and respiratory symptoms (regardless of onset date), patients who after 
admission develop fever and respiratory symptoms (regardless of onset date), and 
individuals (e.g., health care workers, residents, or visitors) with febrile respiratory 
symptoms (within 5 days of onset) connected to an institutional FLU outbreak.
Rhinosinusitis. The IDSA “Clinical Practice Guideline for Acute Bacterial Rhinosinusitis 
in Children and Adults” provides guidance on clinical presentations to identify patients 
with viral and bacterial rhinosinusitis (97). Bacterial rhinosinusitis is defined as any of 
the following (i) 10 days of symptoms without improvement and with onset of high 
fever (102°F [39°C], (ii) high fever with purulent nasal discharge or facial pain during 
the first 3 to 4 days of illness, or (iii) worsening symptoms (e.g., fever, headache, or 
increase in nasal discharge) after apparent resolution of an upper respiratory tract 
infection. This document emphasized the use of clinical approaches and not laboratory 
testing to distinguish between bacterial and viral rhinosinusitis due to the self- limiting 
nature of this illness (97).
Other U.S. and International Guidelines Concerning Specific Populations and 
Settings
SOT. In 2013, the Infectious Diseases Community of Practice of the American Society 
of Transplantation, the American Society of Transplantation, and the Canadian Society 
of Transplantation released guidelines for infectious disease testing on solid organ 
transplant (SOT) patients (98). The guidelines recommend testing for common respi-
ratory viral infections, including FLU, RSV, PIV, hMPV, RV, and CoV (99) with nasopha-
ryngeal swabs, nasal washes, or aspirates. The use of BAL fluid samples should be 
considered for patients with negative upper respiratory tract specimens or with clinical 
or radiological evidence of lower tract disease processes. Multiple approaches may be 
used for diagnosis (e.g., nucleic acid amplification tests [NAATs], direct fluorescent-
antibody [DFA] tests, rapid antigen detection, or culture), but the guidelines emphasize 
that NAAT is the most sensitive approach, and use of multiplexed NAAT improves the 
diagnostic capacity by testing for a variety of targets, which should be seriously 
considered in lung transplant patients. Prophylactic interventions for FLU (vaccination 
and neuraminidase [NA] inhibitors [NAIs]) and RSV (palivizumab) and the use of 
therapeutics for influenza (neuraminidase inhibitors) and RSV (ribavirin/intravenous 
immunoglobulin [IVIG]) are also outlined in the document (99).
The American Society for Transplantation Infectious Diseases guidelines for the 
diagnosis and management of ADV in solid organ transplant patients were published 
in 2013 (100). The document describes posttransplantation timelines for risk of ADV 
infection, where the first three months following SOT represents the highest risk. The 
guidelines emphasize that pediatric patients had the highest incidence of ADV infec-
tion, at 6.25%, which carried an organ-specific risk level (liver  heart  kidney). In 
adult SOT recipients (liver, heart, kidney, and kidney-pancreas), 10.5% of those with 
self-limited viremia after transplant later developed ADV-associated respiratory symp-
toms within the first year. Although ADV subgrouping does not play a role in the clinical 
laboratory, it may provide a sense of molecular epidemiology. For example, respiratory 
tract infections were associated with subgroups B1 (serotypes 3, 7, 16, 21, and 50), B2 
(serotypes 11, 14, 34, and 35), C (serotypes 1, 2, 5, 6), and E (serotype 4), while 
disseminated disease (involvement of two or more organs) was associated with sub-
groups A (serotype 31), B2 (serotypes 11, 34, and 35), C (serotypes 1, 2, and 5), and F 
(serotype 40). Multiple diagnostic approaches can be used for suspected ADV infection, 
including NAAT, culture, DFA testing, and histopathology (considered the gold stan-
dard by the guidelines group for invasive ADV infection), but due to long-term 
shedding in respiratory specimens (as well as urine and stool), detection of ADV is not 
necessarily indicative of a disease process cause by ADV. Clinical symptoms, detection 
of the virus in multiple sites, and histopathology may strengthen the association of ADV 
detection with disease; however, the American Society for Transplantation Infectious 
Diseases guidelines do not offer predictive algorithms to link detection of ADV in
22 days. Preventative measures for FLU include vaccination of close contacts and
antiviral prophylaxis (for close contacts and patients). No recommendations were made
for the use of ribavirin as a preemptive therapy for RSV. Evidence supporting the
efficacy of palivizumab prophylaxis for RSV prevention in HSC recipients 4 years of
age was thought to be insufficient to recommend for or against use. No recommen-
dations were made for prophylaxis of PIV or hMPV infections. Testing for RSV and FLU
in HSC recipients with signs and symptoms of respiratory infection during periods of
circulation was recommended; however, routine surveillance of asymptomatic patients
for these respiratory viruses was not endorsed (101).
multiple sites with disease. The lack of clear clinical cutoffs in qualitative and quanti-
tative NAATs adds to the confusion of whether positive results represent a current 
active infection. Issues with false-negative ADV results with some NAAT panels are also 
described later in this review. The American Society for Transplantation Infectious 
Diseases guidelines indicate that NAAT on a blood sample may be used successfully to 
monitor therapy, particularly if a baseline quantitative value is determined. ADV infec-
tions can be treated with cidofovir; however ribavirin should not be routinely used to 
treat ADV infections even though some subtype C viruses may respond to ribavirin 
treatment (100).
HSC recipients. International guidelines (combined recommendations of the Center 
for International Blood and Marrow Transplant Research [CIBMTR], the National Marrow 
Donor Program [NMDP], the European Blood and Marrow Transplant Group [EBMT], the 
American Society of Blood and Marrow Transplantation [ASBMT], the Canadian Blood 
and Marrow Transplant Group [CBMTG], the IDSA, the Society for Healthcare Epidemi-
ology of America [SHEA], the Association of Medical Microbiology and Infectious 
Diseases Canada [AMMI], and the [CDC]) for preventing infectious complications in 
hematopoietic cell transplant recipients were released in 2009 (101). Patients are at risk 
from respiratory virus infection (FLU, RSV, hMPV, and PIVs) at all transplant stages from 
preengraftment to late phase. Prolonged shedding times after viral infections were 
identified in hematopoietic stem cell (HSC) recipients, with the following potential 
shedding times for the following viruses: ADV, 2 years; FLU, 4 months; and RSV,
Recently, guidelines from the Fourth European Conference on Infections in Leuke-
mia addressed the diagnosis and treatment of RSV, PIVs, hMPV, RVs, and CoVs in 
patients with leukemia and those undergoing HSC transplants (102). The group had 
several recommendations regarding diagnosis of upper and lower tract community-
acquired respiratory viruses, including (i) testing to guide infection prevention and 
control, treatment, and decisions for deferral of chemotherapy or HSC transplant, (ii) 
evidence for collecting specimens from the site of involvement (e.g., pooled swabs for 
the upper respiratory tract and BAL fluid [or tracheal swab if BAL fluid not available] for 
the lower tract), (iii) evidence to support the use of first-line or routine diagnostic tests 
for FLU, RSV, and PIV, (iv) evidence to test for other community-associated respiratory 
viruses based on assessment of risk of exposure and local epidemiology, and (v) 
evidence to consider collection of BAL fluid or biopsy samples for broader respiratory 
viral pathogen testing in patients with lower tract disease. Treatment with ribavirin and 
IVIG was recommended for RSV infection, while ribavirin alone was recommended for 
patients with PIV infection (102).
In 2016, the Infectious Diseases Working Party of the German Society for Hematol-
ogy and Medical Oncology released guidelines for the diagnosis and management of 
community-acquired respiratory viruses (103). The risk of infection with FLU, RSV, PIVs, 
hMPV, and ADV in cancer patients is significant, and infection is associated with high 
rates of pneumonia and mortality. The document highly recommends NAAT for RSV, 
FLU, PIV, and other circulating/prevalent viruses in symptomatic patients. NAAT is 
recommended over antigen detection or culture as the test of choice for identifying 
these viruses. For patients with lower tract infection or critical illness, expanded testing 
for hMPV and ADV (and potentially other rare causes of lower tract disease [e.g., RVs 
and CoVs]) is suggested. Moderate support for recommendations for causal treatment 
of FLU (oseltamivir, zanamivir, and peramivir), RSV (ribavirin and IVIG), and ADV
(cidofovir) was given. Marginal support for recommendations for causal treatments of 
PIVs (ribavirin) was given (103).
Patients in the ED setting. In 2016, the American Academy of Emergency Medicine 
approved a clinical practice paper for the vaccination, diagnosis, and treatment of FLU. 
For seasonal FLU in the emergency department (ED), providers should (104) (i) perform 
testing only if results will change clinical management, (ii) understand the limited 
sensitivity and false-negative rates of rapid antigen detection tests (RADTs), (iii) con-
sider NAAT if clinical suspicion is moderate to high, and (iv) if rapid antigen detection 
tests are negative but clinical suspicion is high, consider empirical antiviral therapy. 
Additionally, FLU antivirals are recommended for patients who are (i) hospitalized, (ii) 
at higher risk for complications, and (iii) have progressive illness (104).
Patients requiring isolation precautions in a health care setting. The Health Care 
Infection Control Practices Advisory Committee (HICPAC) document “Guideline for 
Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings” 
discusses key functions of the clinical laboratory (11). The document recommends that 
microbiologists help guide the limited application of rapid testing to clinical situations 
where this testing influences patient management decisions and that they oversee 
nonlaboratory workers who perform this testing. The document also recommends the 
application of rapid tests to support treatment decisions, bed management, and 
implementation of infection prevention and control measures (e.g., barrier precautions, 
chemoprophylaxis, and vaccination); however, the authors of this PGCM document 
emphasize that the test characteristics (e.g., sensitivity, specificity, and predictive 
values) of an assay should be taken into account when making this decision. Surveil-
lance of FLUA and RSV was emphasized for case finding or cluster analysis, particularly 
when infection precautions may be implemented. Removing a patient from isolation is 
virus specific (see Table 1 regarding isolation precautions); however, of note, RSV 
antigen tests are considered inadequate to remove patients from contact precautions, 
as false-negative results are frequent.
Outbreak investigations. The U.S. CDC guidelines “Unexplained Respiratory Disease 
Outbreaks (URDO)” outline the steps taken to define and investigate a respiratory 
outbreak of unknown origin (105). Detection and characterization of the pathogen are 
key steps allowing for effective clinical management, infection prevention and control 
practices, and defining the time period of the outbreak. The document identifies a 
variety of testing, including NAAT, culture, serology, and antigen detection, that may be 
used to investigate the etiology of an outbreak (105).
Emerging pathogens. In the last few years a number of emerging viruses have been 
identified globally, including FLU subtypes (H5N1, H5N6, and H7N9 [106–108]) and CoV 
strains (MERS-CoV [109]\and SARS-CoV [110]). A number of guidelines have been 
published to help in the diagnosis and management of these emerging pathogens 
(111–113). Optimal timing of collection differs. Although the ideal specimen collection 
time for influenza virus is as soon as possible after symptom onset, NAAT for MERS-CoV 
can be performed 14 days postonset due to improved sensitivity of the assays. From the 
laboratory perspective, NAAT is the recommended method of detection. A wide variety 
of respiratory specimens may also be collected. If upper tract swabs are negative, then 
lower tract specimen collection should be pursued. Although the cultivation of these 
pathogens requires a higher level of biocontainment, the majority of activities for 
identification via NAAT can be done in biosafety level 2 (BSL-2) facility in a biosafety 
cabinet (BSC) using enhanced precautions. As new pathogens emerge (e.g., H7N4), 
laboratorians should confer with reference centers (e.g., the U.S. CDC) on the most 
appropriate testing approaches to detect and characterize these viruses.
(i) MERS-CoV. In June 2015, the most recent version of the MERS-CoV biosafety 
guideline was released as “Interim Laboratory Biosafety Guidelines for Handling and 
Processing Specimens Associated with Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV)—Version 2” (113). Activities appropriate for BSL-2 facilities using standard 
BSL-2 practices included molecular testing of extracted nucleic acid and final packing 
of specimens for transport to diagnostic laboratories for additional testing. Activities to
be undertaken in a class II BSC included aliquoting specimens, diluting specimens, 
performing diagnostic tests not involving propagation of potentially infected speci-
mens, and nucleic acid extraction from potentially infectious specimens. Cell culture 
propagation and the characterization of propagated material should be undertaken in 
a BSL-3 facility using BSL-3 practices (113).
In June 2015, “Interim Guidelines for Collecting, Handling, and Testing Clinical 
Specimens from Patients Under Investigation (PUIs) for Middle East Respiratory Syn-
drome Coronavirus (MERS-CoV)—Version 2.1” was released by the CDC (114). The 
guidelines recommended, when possible, the collection of upper respiratory tract, 
lower respiratory tract, and serum specimens for the diagnosis of MERS-CoV. Potential 
lower respiratory tract specimens included BAL fluid, tracheal aspirate, pleural fluid, and 
sputum. Appropriate upper respiratory tract specimens included NPS and OPS (which 
could be combined in the same transport container if the test is validated for this type 
of combined collection) and nasopharyngeal aspirates. Upper and lower respiratory 
tract specimens should be collected within 7 days of symptom onset; however, NAAT 
can be performed 14 days postonset due to improved sensitivity of the assays (112).
(ii) Novel and emerging FLU strains. In January 2014, guidelines for possible infection 
with avian FLUA (H7N9) virus were released by the CDC (111), and these were later updated 
for novel FLU strains (116). These guidelines outline appropriate testing for emerging FLU 
strains such as A(H7N9) and A(H5N1), and they describe exposure risk and clinical symp-
toms specific for each virus. Specimens should be collected as early as possible after 
symptom onset (ideally within 7 days) (116). Sample collection after this point is still 
relevant in children, immunocompromised patients, and critically ill patients with lower 
tract disease, as virus can be shed for longer periods in these patient populations. As new 
strains emerge (e.g., H7N4), laboratorians should confer with reference centers (e.g., the U.S. 
CDC) on the most appropriate testing approaches to detect and characterize these viruses 
(117).
Acute Respiratory Viral Infection following Travel
The book CDC Health Information for International Travel (also known as the “Yellow 
Book”) (118) is a reference for health professionals who care for international travelers. 
The “Yellow Book” identifies viral pathogens as the most common cause of respiratory 
infections in travelers. Etiologies can vary widely, including infection with RV, RSV, FLU, 
PIVs, hMPVs, ADV, or CoV (118); however, in the absence of severe illness or pneumonia, 
laboratory diagnosis is not always clinically necessary (118). Depending on the travel 
history, novel causes of respiratory illness (e.g., MERS-CoV and avian FLU strains) should 
be considered for symptomatic patients.
It should be noted that the positive predictive value (30 to 88%) for laboratory-
confirmed influenza in returning travelers can vary widely depending on the seasonality 
of infection and method of detection (119). While the negative predictive value of FLU 
NAAT in returning travelers can be used to rule out FLU infection, earlier-generation 
antigen detection test methods should not be used to rule out influenza virus infection, 
particularly when emerging strains are suspected. Patients who should be tested for 
FLU infection include (i) symptomatic hospitalized patients, (ii) cases where diagnosis of 
FLU will affect patient management, and (iii) cases where FLU testing would affect 
infection prevention and control or management of close contacts (119).
Section Summary and Recommendations
Multiple guideline groups have addressed the role of laboratory diagnosis of viruses 
in specific patient populations. Laboratorians should be aware that many guidelines are 
greater than 5 years of age and may not have taken into account the changes that have 
occurred in the types of tests available for the diagnosis of respiratory viruses. Although 
some of these documents are now aging, it is clear that testing may play a more 
important role in the management of severely ill patients and the immunocompro-
mised and less of a role in the management of immunocompetent and relatively 
healthy adults and children. Laboratory testing may assist in supporting public health
investigations (e.g., emerging pathogen investigations and outbreak investigations), 
epidemiological investigations, and infection control functions. Most simply, laboratory 
testing may be considered when it positively impacts clinical decision making and 
supports patient management.
SPECIMEN COLLECTION FOR LABORATORY DETECTION OF ACUTE RESPIRATORY 
VIRUSES
Risk Assessment for Emerging Pathogens Prior to Specimen Collection
During clinical assessment, clinicians should ask about travel history and animal 
exposure that could be consistent with acquisition of (or exposure to) an emerging 
pathogen (e.g., MERS-CoV or avian FLU). Prompt consideration of an emerging patho-
gen based on epidemiological risks with engagement of public health and the imple-
mentation of appropriate of infection prevention and control measures are essential to 
prevent nosocomial spread of these infections. In the MERS-CoV outbreak in South 
Korea (May to July 2015), the lack of prompt identification of risk factors in patients 
presenting to the ED allowed spread between patients and staff at several hospitals 
(120). Early identification and upfront screening procedures could have isolated the 
index patient and reduced the number of contacts, thus limiting the spread of infection 
(121). This is consistent with mathematical modeling showing that rapid identification 
of index cases is the most important factor in reducing spread of infection and that 
patient isolation and quarantine have the strongest correlation with transmission 
prevention (122). As soon as an emerging pathogen is suspected, the laboratory should 
be notified to provide advice on appropriate specimen collection and testing to ensure 
identification and to ensure that the specimens are handled with the appropriate 
biocontainment considerations for the novel pathogen.
Appropriate Specimen Collection Is Critical for Virus Detection in the Laboratory
When to collect a specimen. Clinicians should collect specimens from symptomatic 
individuals with acute respiratory illness within 5 days of symptom onset (preferably 
within 48 h). Specimen collection later than 5 days after onset is recommended only 
when symptoms persist or worsen, in young children, or in the immunocompromised 
(96, 123).
Virus-specific shedding estimates can further direct best collection guidelines for 
respiratory specimens; however, it should be noted that estimates are typically per-
formed on select patient populations, and differences may be due to differences in 
study designs, differences in specimen types, and differences in detection technologies 
between studies (124–126). NAAT is the most sensitive method of detection, and 
sampling as soon as possible after the onset of symptoms is considered ideal for 
healthy individuals; most viral targets can be effectively identified in the first 2 days 
after symptom onset, and multiple studies indicate that viral loads in respiratory 
specimens will generally decrease over time. Furthermore, a delay in specimen collec-
tion following onset of respiratory symptoms will negatively impact the sensitivity of 
laboratory tests to detect a pathogen.
In RV infection, NAAT identified peak shedding within 2 days of symptom onset, 
with decreasing viral loads up to 7 days after onset (127). When virus culture and NAAT 
were both used to test specimens, 57% of human hMPV isolates were detected within 
the first 2 days of symptom onset, while only 19% were detected greater than 4 days 
after onset (128). Only 27% of hMPV NAAT-positive specimens collected after day four 
were positive by culture (128). In children tested for RSV by DFA testing, viral shedding 
(measured in upper respiratory tract specimens [e.g., nasal, throat, and NPS specimens]) 
peaked 2 days after onset of illness, and the median shedding duration was 4.5 days. 
Similar shedding patterns were identified for FLU infection. In community patients with 
acute respiratory illness, FLUA viral loads measured by NAAT peaked at day one 
following symptom onset and were detected until day eight, while in patients who had 
one symptom (but did not meet the case definition for acute respiratory illness), loads 
peaked on day one with detection until day six (129). In contrast, FLUB viral loads were
found to be highest on the day of symptom onset and to persist until day six to eight 
(129).
It should be noted that there are no standard “case definitions” on how long positive 
respiratory virus results detected by NAAT should be considered part of the same 
infection event. Some preliminary studies propose a 30-day period for ADV infection in 
children and for RV infection in infants as a definition of a single case (130, 131); 
however, the temporal definition of a new viral infection should be assessed in the 
clinical context, as the presence of comorbidities can significantly alter viral shedding 
times. The duration of shedding can be influenced by multiple factors. Although prior 
infection may not completely prevent reinfection, it may alter the duration of shedding. 
Older individuals (suggested to have prior exposure) and children with prior RSV 
infection generally shed for shorter periods of time (125, 132). The strain of virus or 
subtype or coinfection with different viruses (133, 134) can also influence shedding 
patterns. RSVA was detected 5.8 days longer than RSVB (135). Similarly, when children 
with acute expiratory wheezing were found to be coinfected with EV and RV, shedding 
of RV persisted for 2 to 3 weeks, whereas EV shedding persisted for 5 to 6 weeks (136).
Other factors may increase shedding time and still allow for productive specimen 
sampling and detection of viral pathogens. Some studies suggest that viral shedding 
may also be extended in patients with more severe disease (125, 137). Shedding can 
also be prolonged in immunosuppressed patients. Although the number of patients 
with detectable virus (FLU, PIV, or RSV) was highest in the first 2 weeks following 
symptom onset, long-term virus detection (30 days) with NAAT on upper and lower 
respiratory tract specimens has been described for FLU, PIV, and RSV in patients with 
hematological disorders (138). Testing these patients for “test of cure” is not recom-
mended or appropriate for viral upper respiratory tract infections, as viral shedding 
often does not represent active infection (139).
Biosafety considerations and PPE required for collection. Respiratory viruses such 
as FLU can be efficiently transmitted through the air (140, 141); however, the direct risk 
to health care workers who are collecting upper and lower respiratory tract specimens 
by different aerosol-generating procedural methods (e.g., bronchoscopy, sputum in-
duction, endotracheal intubation, positive pressure ventilation, nebulizer treatment, 
airway suction, tracheostomy, chest physiotherapy, and high-frequency oscillatory 
ventilation) is currently unknown (142). Analysis of historical data is confounded by 
growing evidence that infection prevention and control practices for respiratory viruses 
may not be uniformly followed (143). A recent analysis of practices in multiple U.S. 
states found low practice adherence, with many health care workers unsure of when 
appropriate personal protective equipment (PPE) should be worn (143). Droplet pre-
cautions for patients with confirmed or suspected infection with FLU should be 
practiced to prevent transmission during collections. The need for N95 masks can be 
controversial, and local infection prevention and control procedures should be fol-
lowed to minimize aerosolization and risk of health care worker infection (144–146). 
Even if more “effective” respirators are used when clinicians are in contact with patients, 
their benefit may be negated if generally poor infection prevention and control 
practices are utilized (145). The laboratorian with expertise in respiratory virus trans-
mission and viral characteristics can be a valuable member of local teams when 
creating respiratory protection program protocols.
Sampling from upper respiratory tract sites: which specimen to use? For an upper 
respiratory tract infection, a variety of specimens can be used to diagnose respiratory 
infections (NPA, NPS, NW, NS, OPS/TS, and sputum) (Table 3), and the U.S. CDC offers 
collection guidance for each; however, laboratories should use manufacturers’ recom-
mended specimen types in U.S. Food and Drug Administration (FDA)-cleared or vali-
dated/verified laboratory tests (147, 148). Selection of specimen type is dependent on 
a variety of factors: patient age, patient willingness to undergo a specific procedure, 
clinical presentation, the nature of the potential pathogen, and the appropriateness of 
the specimen type for verified laboratory diagnostic approaches. Although a combi-
nation of different specimen types can improve the sensitivity of NAATs (149–155), this
TABLE 3 Sensitivity of respiratory viral detection from different specimen typesa
Specimen type
Sensitivity of detectionb of:
FLUA/Bc RSV RV/EV ADV hMPV PIVs CoVsc
NPS       
NPA       
OPS ()d      
TS       
Sputumf      () ()e
BAL fluid      () 
Lung biopsy specimen      o 
aFor specimen collection, it is important that appropriate infection control practices are followed, as 
collection can be aerosol generating. FDA clearance and laboratory-based validation/verification of the 
specimen source for assay need to be considered. Appropriate collection methods should consider 
downstream testing to ensure that specimens are handled, stored, and shipped properly prior to testing. 
Preanalytical specimen storage information provided by the laboratory should indicate storage temperature, 
retention time, and stability of the specimens (123, 178, 179, 370). Combinations of different specimen 
types can significantly increase the yield for viral detection. Results for nasal specimens are not included in 
this table because the literature describing their efficacy in detection is variable (372–374).
b, specimen type has high detection rates for the indicated virus; , specimen type is acceptable for 
viral detection, but sensitivity may be reduced due to the sampling or testing method used for detection; 
, specimen type has reduced sensitivity for indicated virus; (), minor reduction; (), moderate 
reduction; o, limited utility.
cFor emerging avian influenza virus strains or for CoVs such as SARS-CoV or MERS-CoV, lower respiratory 
samples are additionally recommended for enhanced detection.
dNPS were more sensitive for detection of FLUB, while OPS were more sensitive for FLUA strains (153). 
eSputum sensitivity varies between CoV strains (180).
fSensitivity of sputum results can vary widely depending on the quality of the specimen received. Sputa 
received for viral testing are not screened for specimen adequacy as for those received for bacterial workup 
(371).
must be balanced in such a way to maintain high detection rates yet still maintain a 
cost-effective approach. For emerging pathogens (e.g., novel FLUA H5/H7/H9 or emerg-
ing CoV), a collection of multiple different types (OPS, NS, NPS, BAL fluid, etc.) may be 
necessary to identify specimens that most reliably result in detection of the pathogen. 
Depending on the pathogen (e.g., emerging CoV or novel FLUA), other, atypical 
specimens such as blood or stool for direct virus detection may also be suggested for
collection (156–158).
Traditionally, NPA were used as the gold standard for detection of respiratory viruses
(159). Previous publications suggest that NPS is equivalent to NPA for the detection of
multiple viruses in children (160). Although NPS/NPA are generally more sensitive than
throat swabs for detection of most viruses (152, 154, 161, 162), NS are easier to obtain,
are less painful (163–165), and can be self-collected with yields equivalent to those
collected by a clinician (166). Reduced diagnostic sensitivity using NS samples is often
considered an acceptable trade-off for increased compliance, particularly when the
prevalence of disease is high (159, 167). In addition, there are increasing data suggest-
ing that the combination of both an NS and an OPS in adults and children has a yield
equivalent to that of NPS/NPA (10, 151, 155). Use of a flocked swab with a liquid viral
transport medium may additionally improve viral detection (161, 168, 169). Easier
midturbinate collection with flocked swabs may provide an alternative to proper
nasopharyngeal specimens, albeit with potentially a lowered sensitivity (170, 171). 
Finally, when using commercially available rapid antigen detection tests (RADTs), 
laboratories should use the kit-recommended swab unless the performance of the test
with a different specimen type has been verified (172).
Approaches to specimen collection from the lower respiratory tract. Lower respi-
ratory tract specimens such as sputum, bronchoalveolar lavage/wash, and lung tissue 
may be considered in cases where the patient may be infected with an emerging
pathogen (173, 174) or is under intensive/critical care for pneumonia (175), in cases
involving autopsy (176), or where molecular detection requires pathological evidence
of invasive disease (e.g., ADV infection in lung specimens of lung transplant patients)
(177). In severe illness due to influenza and emerging pathogens, upper respiratory
tract sampling may yield false-negative results (112). Accurate diagnosis in these cases 
often will require a variety of specimens from the upper and lower respiratory tracts. 
Selection of lower respiratory tract specimens should be dependent on the disease 
course (e.g., anatomic location of the diseases process, stability of the patient/risk in 
sampling, and ability to access the anatomic site) (176, 178–180). Given these issues, 
specimen collection and therefore determination of the lower respiratory tract infection 
may not be possible.
Lower respiratory tract specimen types vary in their ability to be used to detect 
specific viral etiologies (Table 3). Sputum may be considered an appropriate specimen 
for sampling the lower respiratory tract in some patients (178–180). However, data are 
limited. Specimen viscosity and higher rates of PCR inhibition make sputum a more 
difficult specimen type to use in the laboratory (174), and most FDA-cleared assays for 
respiratory viruses are not validated by the manufacturer for sputum or other lower 
respiratory tract samples (e.g., BAL fluid). Bronchial washes and lavage fluids can be 
useful specimen types, provided that they are collected appropriately in sterile con-
tainers, as the viral load for lower respiratory tract infections can be higher in these 
specimen types. Lung tissue collected during bronchoscopy, open surgical procedure, 
or autopsy should be placed in a sterile container with a small amount of sterile saline 
to keep it moist (176). Specimens should not be put into formalin, as it reduces the 
sensitivity of NAAT, and formalin-preserved samples are not commonly verified sample 
types for most laboratory test systems. Procedural variability for specimen collection 
(e.g., volumes collected and dilution factors) makes comparison of the performances of 
these off-label specimens difficult.
Transport medium and transport considerations. Viral transport medium or uni-
versal transport medium facilitates viral culture, direct fluorescent-antibody (DFA) 
testing (181), rapid antigen detection tests (RADTs) (182), and molecular testing (181, 
183, 184). Stability guidelines outlined in the package insert (storage at room temper-
ature, refrigeration, or freezing) should be used as per the manufacturer’s instructions. 
Other transport devices may be considered (e.g., dry swabs [185, 186] or alcohol-based 
transport medium [185]) but are not widely used. Transport should be in accordance 
with regulators’ guidelines in each jurisdiction.
Section Summary and Recommendations
Always ensure that clinicians are aware of processes for safe specimen collection 
from patients who are suspected of being infected with routine and emerging respi-
ratory viruses. For the detection of routine seasonal respiratory viruses, samples should 
be collected as early as possible from patients following onset of illness. Shedding 
studies of multiple viruses indicate that viral titers drop daily following the onset of 
illness. Thus, sampling from patients at later time points is expected to negatively 
impact the sensitivity of diagnostic assays. Sample collection from the upper respiratory 
tract may be easiest, but upper tract sampling may not detect viruses causing lower 
tract disease. Following specimen collection, ensure that appropriate transport and 
storage conditions are used for specimens.
LABORATORY DETECTION OF ACUTE RESPIRATORY VIRUSES
The Role of Cell Culture is Limited
Cell culture was long considered the gold standard for virus isolation and identifi-
cation prior to the availability of molecular assays (187, 188). Modification of cell lines 
(including primary lines, immortalized lines, mixed cell lines, and transfected lines) has 
improved the ability to detect respiratory viral pathogens (189). For laboratories 
offering cell culture analyses, detailed procedures can be found in the Clinical and 
Laboratory Standards Institute document “M41: Viral Culture.” (190).
There are a variety of drawbacks to using cell culture compared to molecular 
methods, and many virology laboratories have opted to discontinue viral culture in the 
laboratory for these reasons. It is well established that cell culture has a lower sensitivity 
than molecular techniques (191, 192), the turnaround time and hands-on time required
to perform cell culture compared to molecular testing are increased, and the technical 
expertise for performing cell culture is often not available. Traditional tube cultures are 
slow and can take up to 10 days for detection of respiratory infections (36). A study in 
pediatric patients indicated that positive viral culture results would not impact the 
management of healthy children hospitalized for illness attributed to community-
acquired respiratory viral infection due to the delay in time to culture positivity (193). 
Shell vial assays can decrease the time to detection; however, 1 to 2 days is still required 
for growth and identification of the virus. Care must be taken when selecting cell lines 
for viral growth, as not all cell lines will allow for propagation of all viruses, and cell lines 
may be viral strain specific (194). Yields from cell culture are often decreased following 
freezing, due to reduced numbers of viable virus particles; therefore, samples that are 
frozen prior to culturing may be falsely negative (139, 195). As a safety note, culture 
approaches may inadvertently propagate emerging pathogens and compromise labo-
ratory biosafety (195); however, maintaining cell culture capabilities in public health 
laboratories remains important for identification of unknown or emerging pathogens, 
particularly when specific molecular amplification processes are not available, and can 
provide an understanding of the virus viability within a clinical specimen (196).
Direct Fluorescent-Antibody and Immunofluorescent-Antibody Assays for Respi-
ratory Viruses
Direct fluorescent-antibody (DFA) and immunofluorescent-antibody (IFA) assays 
have been used to detect a variety of respiratory viruses from primary specimens 
(chromatographic immunoassays for the detection of respiratory viruses are discussed 
in the following section). Commercial and standardized clinical reagents are available 
for select respiratory pathogens (e.g., FLUA/B, PIVs 1 to 3, ADV, hMPV, and RSV) (197). 
Like that of traditional cell culture techniques, the quality of DFA/IFA assays is impacted 
by specimen quality and collection method (171). Unlike the case for traditional cell 
culture, DFA and IFA assays do not require viable viruses and the turnaround times are 
short (4 h) and on a single-specimen basis can be shorter than those for older 
laboratory-developed molecular approaches (which have, e.g., separate extraction 
steps, greater numbers of manual steps, and manual interpretation and data entry in 
laboratory information systems) or batched-based testing; however, DFA/IFA technol-
ogies are labor-intensive, require a skilled technologist to read and interpret results, 
require a fluorescence microscope, and are subject to reader error. Furthermore, the 
hands-on time required per test is not structured for high-throughput result reporting. 
Compared to molecular detection methods, DFA and IFA assays have significantly 
reduced sensitivity and specificity (197). Some argue that the lower sensitivity can 
identify “clinically relevant infections” in some patient populations (e.g., hospitalized 
pediatric patients) (198) in contrast to detection of free nucleic acid as in molecular 
detection. Additionally, microscopic examination of samples for DFA testing can di-
rectly determine specimen quality (199) by allowing for observation of the number of 
epithelial cells present in the sample.
Rapid Antigen Detection Tests for the Detection of Respiratory Viruses
Clinical Laboratory Improvement Amendments (CLIA)-waived tests are intended for 
use in “professional” settings (e.g., physicians’ offices, mobile clinics, and pharmacies) 
and/or by untrained operators with no laboratory expertise (200). A summary of rapid 
antigen detection test (RADT) technologies that may be used as near-patient or 
point-of-care (POC) tests is given in Table 4. Technologies for these guidelines are 
discussed in general here; specific products are not discussed, and company names are 
not mentioned.
Earlier RADT assays detected antigens of FLUA, FLUB, and RSV. Use was often 
restricted to specific specimen types (e.g., NPS or NS), the sensitivities of these assays 
in pediatric and adult populations varied but were considered to be poor, and the 
assays could not be used to rule out infection (201, 202). Performance characteristics of 
these assays were typically determined during normal respiratory virus seasons, with
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acceptable specificity for RSV and FLU (203, 204); however, the performance charac-
teristics are significantly reduced when assays are used out of season (205–207). Many 
believe that the clinical utility of employing FLU and RSV POC assays, given the high 
numbers of both false-positive and false-negative results, is questionable (205–207), 
and the future long-term availability of rapid antigen detection kits is in doubt. On 23 
February 2017, the U.S. Food and Drug Administration (FDA) reclassified rapid antigen 
influenza virus test kits from class I to class II medical devices (208). This was meant to 
address growing concern about the variable performance of these assays as well as 
poor sensitivity compared to other methods such as NAATs and culture. Existing kits 
could be purchased until 12 January 2018 and used until the kit expiry date. Following 
that point in time, manufacturers were expected to monitor kit reliability and provide 
updates to users. Additionally, some assays are unable to differentiate between FLUA 
and FLUB, which may impact epidemiological investigations (209), and they have 
particularly poor sensitivity to detect avian influenza virus and other emerging sub-
types (210). However, RADT may still have a place in management of outbreaks or in 
locations with limited access to molecular diagnostics (209), but consideration of the 
assay performance and the seasonality should be taken into account when using these 
assays.
A second generation of viral antigen POC tests improved the sensitivity for FLUA/B 
and RSV detection compared to that of earlier technologies (211, 212); however, the 
performance characteristics were still reduced compared to those of routine molecular 
testing (Table 4). Similar to the case for earlier generations, respiratory viral infection 
could not be ruled out with the newer POC tests, and sensitivities and specificities 
varied depending on the FLU target and the comparator molecular method used (Table 
4). For RSV, sensitivity and specificity were reduced compared to those with molecular 
methods (Table 4). The sensitivity of these tests is highest during the RSV season when 
the positive predictive value is high (213–215). If clinicians feel there is a need for RSV 
antigen-based POC testing for pediatric patients (e.g., when there is no nearby labo-
ratory access or in resource-poor environments), laboratorians need to inform clinicians 
of the newer test technologies, provide information on the current prevalence of these 
pathogens, and assist in generating algorithms that reduce the risks of these technol-
ogies.
Molecular Detection Approaches as the New Reference Standard
Extraction considerations. The first step in NAAT requires extraction, purification, 
and preservation of target organism nucleic acids. Extraction technologies should be 
able to cleanly isolate both high-quality viral RNA and DNA and, depending on the 
assay, to additionally sample human nucleic acids to allow the detection of human 
genes (e.g., that for glyceraldehyde 3-phosphate dehydrogenase [GAPDH] or 2-
microglobulin [2M]) as control targets. The ubiquitous presence of RNase enzymes in 
most human samples makes isolation of RNA nucleic acid targets (e.g., FLU, RSV, and 
CoV) (Table 1) more difficult than isolation of DNA (e.g., adenovirus) (Table 1) and often 
requires additional steps for processing. Multiple extraction methods may be employed 
for respiratory virus detection. Heat-mediated lysis is an approach where target organ-
isms are lysed or homogenized to release target nucleic acids (216). This approach is 
used in some commercial NAATs. Manual extraction using phase separation, capture via 
magnetic beads, or immobilized silica spin or vacuum wash columns may also be used. 
Automated extraction systems may be employed and generally use magnetic silica or 
other particles designed to capture RNA, DNA, or both. In fully automated instrument 
systems, all steps from extraction through to amplification are incorporated into a 
single cartridge or pouch.
Commercially available respiratory virus NAAT kits for detection of respiratory viral 
targets generally have a specific extraction method that is qualified for sample pro-
cessing as part of the FDA clearance. Often, the FDA-cleared NAATs will have claims for 
specific specimen types (NPS, NS, etc.) but may or may not specify the type of transport 
medium. If the laboratory chooses to use specimen types besides those that are FDA
cleared, the laboratory should perform a verification study to document recovery of the 
target nucleic acids and acceptable performance of the NAAT (217). A validation plan 
should consider a variety of factors, including the frequency of specimen type being 
tested and the risk that specimen types may not be compatible with the assay. 
Similarly, if the testing laboratory chooses to use a different extraction protocol, 
verification for comparable performance is required. The requirement for verification of 
additional specimen types is outlined in the College of American Pathologists’ Micro-
biology Checklist, Molecular Microbiology, MIC.64810 (sections titled “Test perfor-
mance—manufacturer’s instructions” and “Laboratory-developed or modified FDA-
cleared/approved tests”) (217). Many in-depth documents and reviews discussing the 
requirements of molecular assay validation have previously been published (218, 219); 
therefore, a detailed discussion will not be included in this article.
Assay control considerations. All NAATs, whether laboratory-developed tests (LDTs) 
or FDA-cleared assays, should include a set of controls, including external positive and 
negative controls for respiratory viral targets that are tested by all steps in the assay. An 
internal amplification control should be added to all specimens except in assays where 
inhibition rates of the NAAT have been shown to be below acceptable limits (often 
defined by the laboratorian) (220, 221). These controls ensure that target nucleic acid 
is recovered and any potential NAAT inhibitors are removed during the sample 
processing stage. While commercial NAAT kits are designed to flag invalid results (when 
internal controls fail), LDTs require manual checks and result review to detect invalid 
specimens. The number of external controls and their frequency of use should be 
established by the laboratory based on regulatory requirements and its individualized 
quality control plan (IQCP), with a focus on risk assessment. Rules for review and 
result-based actions items should be addressed in the laboratory IQCP (222, 223).
Contamination. Molecular target amplification assays are susceptible to false-
positive results caused by contamination, and false-positive results may occur at any 
step in sample collection and processing. Preanalytical contamination may occur when 
specimen integrity is breached during the collection process or when integrity is 
breached during early handling processes in the laboratory (221). Even when using a 
biosafety cabinet, steps should be taken to limit the production of aerosols and to 
process specimens in a manner that prevents cross contamination (224). Given that 
respiratory viruses can be identified in health care environments, it is possible that 
inappropriately handled swabs or other specimens could be contaminated with these 
viruses (225). It is also possible that a laboratory worker infected with a respiratory virus 
may act as a contaminating vector in the laboratory. The greatest risk of contamination 
is from amplicons created (and possibly aerosolized) during previous molecular runs. 
Most commercial assays using either real-time reporters or array-based detection are 
designed to minimize risks of amplicon contamination unless the laboratorian fails to 
correctly handle the reaction vessels (221).
Assays that incorporate manual postamplification processing present the highest 
risk of contamination to the laboratory. Multiple amplicon sterilization processes have 
been established to decrease the chance of amplicon carryover in molecular assays. 
These include the use of UV light to create thymidine dimers (cross-linking contami-
nating DNA), altered amplification chemistry using modified nucleotides, addition of 
uracil DNA glycosylase (UNG), and the use of hydroxylamine to prevent cytosine and 
guanine base pairings in subsequent reactions; however, numerous chemical ap-
proaches may be used (226–228).
Good laboratory practices can also be used to control contamination or carryover of 
amplicons (Table 5). These are particularly relevant when multiple processes such as 
reagent preparation, nucleic acid extraction, amplification, and postamplification pro-
cessing are utilized. Open systems (where extraction, amplification, and/or detection 
stages are exposed to the environment) and closed systems (where extraction, ampli-
fication, and detection are completed within a single compartment not exposed to the 
environment) have different contamination control requirements (Table 4). Staff train-
ing protocols and laboratory standard operating procedures (SOPs) should emphasize
TABLE 5 Good laboratory practices for molecular assays
Laboratory practice to decrease contamination events
Recommendation for type
of molecular systema
Open Closed
Unidirectional flow (clean to dirty) Recommended Not required
Physical separation of pre- and postwork areas Recommended Not required
Regular decontamination of work areas Recommended Recommended
Use of aerosol-resistant pipette tips Recommended Recommended
Change of PPE between processing steps Recommended Not required
Restricting worker movements postamplification Recommended Not required
Centrifuging reagents Recommended Recommended
Ensuring that only one specimen is uncapped at a time Recommended Recommended
Process to monitor contamination events Recommended Recommended
Dedicated equipment for pre- and postamplification areas Recommended Not required
Monitoring environment for contamination (e.g., by environmental swipe tests) Recommended Recommended
aBased on the type of molecular system, laboratory practices to decrease contamination are either recommended or not required (217, 221–223, 228).
the organization of workflow process (such as unidirectional flow, separate areas for 
pre- and postamplification processing, regular decontamination of work areas with 
bleach, strict adherence to use of aerosol resistant pipette tips, mandating changing of 
gloves and lab coats between processing steps, and restricting work on new samples 
after handling postamplification reaction mixtures [228]) and technical practices (such 
as aliquoting of reagents, centrifuging of reagents, and care in capping and uncapping 
tubes, which may also prevent cross contamination). Physical separation of workspaces 
dedicated to different assay steps (e.g., pre-PCR and post-PCR) can also decrease the 
risk of contamination (221) and is recommended for open systems, but it is not 
necessary for closed systems.
Additionally, laboratorians should develop processes to monitor contamination 
events. Sentinel systems, such as running negative or no-template controls in each 
amplification assay, can be used for detecting large-scale contamination (221), while 
low-level contamination events may be identified by laboratorians as an excessive or 
unusual amount of low-level positive specimens (e.g., positive results near the cutoff). 
Care should be taken when interpreting results for higher numbers of low-level positive 
results outside the normal respiratory virus season, as many low-level positive results 
may represent contamination. Care should be taken when interpreting specimens that 
are positive for multiple targets, and laboratorians should have a sense of the coinfec-
tion rates within their settings. Coinfection rates may vary widely between adult and 
pediatric patient populations and may account for over 10% of all specimens in some 
pediatric populations (229–231). Environmental swipe tests should be considered to 
monitor workspaces for contamination from current or recently circulating viruses as 
well as control materials, and they can be used to detect widespread amplicon 
contamination events (232); however, sporadic contamination events may be missed 
due to sampling bias. Some FDA-cleared assays have specific recommendations for 
environmental monitoring and outline routine decontamination measures. For other 
tests, it is up to the laboratory to define intervals as part of their quality assurance 
program or IQCP (217, 221–223).
Positive predictive value and false-positive tests. In general, molecular tests for 
respiratory viruses have high sensitivity and excellent negative predictive values, which 
can reliably rule out infection when assay results are negative. Most molecular assays 
for respiratory viruses also have excellent positive predictive values, in the range of 90%
or higher. Because molecular amplification assays for these pathogens are generally 
more sensitive than culture-based methods (233), it is often difficult to determine if a 
molecular result is a false positive when the reference culture method is negative. In 
some instances, a second molecular assay using a different gene target may be used to 
resolve discrepant results; however, it should have analytical sensitivity equal to (or 
better than) that of the first assay (220). Additionally, when the respiratory viral 
pathogen is present at a level close to the assay’s limit of detection, discrepant results
(ii) Recommendations for patient populations in which multiplexed respiratory
due to Gaussian distribution effects can be observed (234). Finally, sampling error can 
affect the results of comparative studies if two separate swabs or collection protocols 
are utilized.
Labor and cost of molecular assays. The use of molecular approaches has tradi-
tionally been accompanied by higher supply costs than for antigen- or culture-based 
methods (235); however, modern molecular technologies provide improved perfor-
mance characteristics compared to culture and/or DFA/IFA (197). Automation and 
integrated molecular test platforms can provide labor savings to the laboratory to offset 
increased reagent and platform costs (236) and may also decrease downstream costs 
for the health care system by providing more rapid and accurate results. Incorporation 
of molecular assays has resulted in variable patient management outcomes depending 
on studies, with some studies showing positive effects and other studies showing no 
effect, as identified in a recent review by one of the authors of this article (237). 
Negative effects on patient management have not been identified. Positive effects on 
patient management include decreased patient isolation times (238), length of stay 
(LOS) (239), administration of antibiotics and oseltamivir (240), and duration of antibi-
otic therapy (241).
Understanding Applications of Molecular Detection Approaches
Limited role of viral loads in predicting patient outcomes. A growing body of 
evidence shows a correlation of respiratory viral load and patient outcome. In one study 
of immunocompetent adult patients, age and hospitalization time were associated with 
earlier reverse transcriptase PCR (RT-PCR) cycle threshold (CT) values for FLUA/B of 20 
than later CT values (242). Association of viral load and outcome can also vary by 
genotype, as RV-A viral loads were higher in patients with severe disease than in 
patients without severe disease, while no difference in viral load was observed for 
patient groups infected with RV-C (243). Furthermore, increased fatalities in adult CAP 
patients were associated with sustained viremia and high viral loads of ADVs in sputum 
and tracheal aspirates (244).
However, current laboratory practices generally report qualitative results for a 
respiratory virus NAAT, rather than determining a true viral load. The currently available 
laboratory-developed viral load assays have multiple problems, including the lack of an 
international standard, lack of standardized technology, and lack of consensus on 
specimen types (245). Additionally, the timing of specimen collection can influence viral 
load results. In fact, viral load samples taken on day 3 postonset may have a stronger 
association with clinical outcome than samples taken on day 0, 1, or 2 (246). Given the 
viral load data described in this section, the viral shedding data (described above), and 
the impact of age, immune status, and/or coinfection with other respiratory viruses 
(134), additional studies are needed to determine when viral loads are appropriate in 
different patient populations and how to appropriately interpret the results. Due to 
sampling errors, time of collection, patient age, etc., viral loads may not be comparable 
from one patient to another. In the future, possible roles for these viral load assays may 
include monitoring an individual patient over time to assess for viral clearance or 
response to antiviral therapy.
Molecular panel testing for respiratory viruses. (i) Defining multiplex assays. 
Multiplexing of molecular assays was traditionally restricted by the number of targets 
that could be efficiently amplified within a single reaction vessel (247–249). The earliest 
approaches were often batch-based assays that relied on a single nucleic acid extrac-
tion followed by one or more molecular assays. Often, panels of multiple individual 
targets or small multiplexes with 1 to 3 targets could overcome some of the inefficacies 
of massively multiplexed reactions (250); however, development of new technologies 
with improved multiplexing capabilities has allowed detection of multiple virus targets 
from a single sample (251–253).
viral panel testing may be appropriate. Testing requirements may vary depending on 
the patient setting and resources, as the costs of the multiplex assays are high. The
most appropriate patients to test may vary depending on the health care setting, as 
some studies show questionable utility in testing adult outpatients for viruses other 
than FLU (254), Instead, for FLU patients who meet ILI criteria and are at high risk for 
complications, a highly accurate rapid test may have the greatest utility. Others have 
shown that multiplexed viral panels can directly influence antibiotic utilization practices 
(241).
Hematology and oncology patients may be appropriate patient populations for 
testing. The Infectious Diseases Working Party of the German Society for Haematology 
and Medical Oncology identified community-acquired respiratory virus infection as a 
significant cause of morbidity and mortality in oncology patients (103). Infectious viral 
etiologies were widely varied and included both single and mixed infections. For 
example, RSV infection has a high likelihood of progressing to a lower respiratory tract 
infection (30%) and a high chance of mortality (27%) in oncology patients. Therefore, 
testing for FLU, RSV, PIV, and other prevalent community-circulating viruses in all 
oncology patients presenting with symptoms (103) is suggested.
Transplant patients may also be an appropriate patient population for multiplex 
testing. Given the poor predictive value of the U.S. CDC’s ILI criteria not only in adult 
transplant patients but in general, some authors have suggested an increased role for 
the use of multiplex respiratory NAAT assays in adult transplant patients with suspected 
respiratory virus infection (32). In lung transplant patients, identification of mixed viral 
infections using a multiplex panel could be used as a predictor of poor outcome (e.g., 
biopsy-proven rejection or sustained decline in forced expiratory volume [FEV1]) (255). 
In lung transplant patients, the detection of one or more viruses using a respiratory 
virus panel in a BAL fluid sample during the first year after transplant has also been 
associated with significantly faster development of bronchiolitis obliterans syndrome 
(BOS) (256).
Intensive care unit (ICU) patients may be another appropriate patient population for 
respiratory viral multiplex panel testing. In a recent review, respiratory viruses such as 
FLU, RSV, and RVs were suggested to cause immunosuppression in ICU patients (257). 
Given the clinical severity of illness in patients in the ICU, they are good candidates for 
respiratory virus panel testing. Appropriate identification of the severity of patient 
illness as well as the patient location (including the ICU) within the health care facility 
can often be challenging for the laboratory. Therefore, identification of critically ill 
patients with suspected pneumonia has previously been used as a selection criterion in 
the absence of accurate hospital location data (258).
Pediatric patients with an underlying illness may also be an appropriate patient 
population for respiratory viral panel testing. Panel testing may allow for identification 
of pathogens associated with specific risks in pediatric patients. This may include 
increased risks for asthma and wheezing in critically ill patients (259) or a lack of FEV1 
improvement in pediatric cystic fibrosis patients (260).
(iii) To multiplex or not to multiplex? A variety of commercial and FDA-cleared in 
vitro diagnostic tools are currently available. Incorporation of these highly multiplexed 
assays into the laboratory significantly decreases turnaround time compared to that 
when performing all assays individually (252). Additionally, ease of use is improved with 
many assays giving “sample-to-answer” detection of respiratory viruses. Multiplex 
assays often have excellent performance characteristics, allowing clinicians to be 
confident with test results and make informed clinical decisions with concrete patient 
and health system benefits. Compared to complex algorithms involving multiple 
ordering of tests for small numbers of viral targets (e.g., FLU, FLU/RSV, EV, and RV 
alone), multiplex panels used as a routine test ordering choice can remove some of the 
confusion or indecision described by clinicians when ordering tests for smaller numbers 
of viral targets individually (261, 262). However, given that these panels are expensive, 
demonstration that the results impact patient care help justify the increased cost to the 
laboratory. A variety of studies have looked at indirect benefits of multiplexed panel 
testing; however, the identified outcomes are not consistent between studies. In 
patients 3 months to 21 years old, panel use has been associated with decreased length
of stay (LOS) in emergency departments and inpatient wards (241). Identification of a 
viral etiology has also shown improvements in hospital isolation resource use, which 
can be removed as appropriate and targeted only to patients who require isolation. 
Compared to other methods, multiplex panels can decrease the amount of antibiotic 
and antiviral use, and they may be used to appropriately triage patients in acute care 
settings (239, 263, 264). A significant decrease in the duration of antibiotic use and the 
number of chest radiographs was observed in an adult tertiary care center when rapid 
multiplexed panels were used compared to traditional antigen detection and older 
molecular methods (239). Adult outpatient outcomes were assessed at a Connecticut 
VA Center that used an on-demand respiratory panel. Outpatients were divided into 
those with FLU detected, those with a non-FLU virus detected, and those with no 
pathogen detected. Antibacterial prescription rates did not vary between groups; 
however, there was a statistically significant difference between antiviral prescription 
rates: the FLU-positive group was more likely to be treated with an antiviral agent 
(80/105 [81%] treated) than were patients in the non-influenza virus pathogen group 
(6/109 [5.5%]) and the no-pathogen-detected group (2/81 [2.5%]) (P  0.001) (254). 
Respiratory panel use allows for more comprehensive characterization of viruses for 
general epidemiology/surveillance (15, 265) and outbreak investigation. Other, less 
tangible but important, benefits to respiratory viral panel use may also include im-
proved patient and physician satisfaction with an improved test turnaround time.
Multiplexed respiratory virus panels may have significant costs for implementation, 
and some may have significant costs to operate. Health care administrators need to be 
made aware of the indirect and direct benefits of panels and how cost savings may be 
generated through improved workflow practices and lower labor costs (266, 267). 
Laboratorians and clinicians may need to reassess how clinical utility studies are 
undertaken and consider group efforts to undertake well-controlled and standardized 
studies (264).
(a) Multiplexing and the utility of identifying mixed infections. Multiplexing of molecular 
assays can facilitate identification of mixed viral infections (268–270). Coinfections are 
defined as the detection of more than one virus in a patient specimen. The rate of 
coinfection will depend on the particular virus, the methodology used for detection, 
the patient population demographics, and the geographic location of the study (271). 
However, understanding the impact of coinfections on patient outcomes is challenging, 
particularly when molecular tools are used for diagnostics. Nonviable virus from a 
remote infection or virus not associated with the current infection may be detected by 
molecular methods. Important considerations include (i) whether identification of 
mixed infections leads to a better understanding of patient prognosis, (ii) whether 
identification of mixed infections leads to changes in patient management, (iii) whether 
identification of mixed infections leads to changes in infection prevention and control 
practices, and (iv) whether the increased identification of viruses not routinely identi-
fied in nonmultiplex panels allow for placing patients in cohorts based on etiology 
during isolation.
In some cases, coinfections may make up a significant proportion of total viral cases 
within a population. In one recent study, coinfections with bacteria and viruses were 
identified in 40% of viral respiratory tract infections requiring hospitalization (272). For 
example, in Japan, a recent study found that 43.8% of patients who were diagnosed 
with a CoV infection were also infected with an additional virus (273). In another study, 
coinfections of two or more viruses were identified in approximately 18% of infants 
with an acute respiratory illness; RV was the most common coinfecting virus, but other 
viruses, such ADV, hMPV, and PIVs, were also codetected (270). Thus, the impact of 
mixed infection on patient outcomes is still under debate. Some studies show no 
difference in patient outcomes when coinfections are compared to single virus-
infections, even in highly immunocompromised patient populations (268). Additionally, 
studies in immunocompetent children with lower respiratory tract infection found that 
RSV coinfection with any other respiratory virus was not associated with more severe 
disease than RSV infection alone (274). Conversely, other studies show that coinfection
with RSV and a second virus in infants with lower respiratory tract infections is 
associated with increased length of stay (LOS) (275). In another study, an increased risk 
of life-threatening disease (e.g., intensive care unit [ICU] admission, need for mechanical 
ventilation, or death) was identified in patients with ADV-RSV coinfections compared to 
RSV single-virus infections. In a secondary outcome analysis, FLU-RSV coinfections had 
an increase in LOS compared to RSV single-virus infections (274), while ADV coinfec-
tions were more likely to be associated with the need to treat with supplemental 
oxygen than were ADV single-virus infections (276). Furthermore, in cases of 
community-acquired pneumonia, viral-bacterial infection has been associated with a 
more complicated course (e.g., hospital death or mechanical ventilation for 7 days) 
than infections with bacteria alone, viruses alone, or no identified etiology (277).
(b) Commercially available molecular test panels may not fulfill all testing needs. A major 
drawback of multiplexed panels is the inability to differentiate closely related viruses or 
to detect all targets with equivalent sensitivity, and some targets on commercial 
multiplex panels continue to be detected more efficiently by singleplex assays (278)
(also see comments on emerging pathogens below). In one study, detection of RSVA 
and FLUA had decreased sensitivity in panel tests compared to that with singleplex 
NAAT (279). Likewise, detection of ADV in multiplex panels often has decreased 
sensitivity compared to that with in-house NAAT assays (280), particularly for ADV 
group E (279). Of note, only respiratory species of ADV (B, C, and E) will be detected in 
multiplex panels, while nonrespiratory ADV species (A, D, and F) will be missed. In 
commercial panels, the proprietary nature of primers and probes does not allow 
investigation for detection of emerging viral pathogens, which may be missed by 
commercial assays (281).
Another limitation in some available assays is the inability to distinguish EVs from 
RVs. This can lead to secondary laboratory differentiation algorithms to characterize 
infection (282), and this is compounded by the limited ability to detect emerging EV 
strains (278). For example, enterovirus D68 may require altered patient management 
compared to seasonal EV strains, as it is associated with extrapulmonary syndromes 
such as acute flaccid paralysis (282). Additionally, detection of nonrespiratory ADV in 
the respiratory tract can precede systemic infection in immunocompromised children 
(283). Unfortunately, there is currently no practical gold standard to determine whether 
ADV detection in the respiratory tract is causal or incidental (284).
(iv) Near-patient or POC tests. As highlighted above, CLIA-waived tests are in-
tended for use in “professional” settings (e.g., physicians’ offices, mobile clinics, and 
pharmacies) and/or by untrained operators with no laboratory expertise (200). A 
summary of NAAT assays that can be used as point-of-care (POC) or near-point-of-care 
tests is in Table 4. Technologies for these guidelines are discussed in general here; 
specific products are not discussed, and company names are not mentioned.
The availability of newly developed CLIA-waived NAAT assays which detect FLUA/B 
or both FLUA/B and RSV is increasing. Multiple assays are now emerging in the 
marketplace and may have similar test characteristics (285); users should consult 
up-to-date resources for a list of waived products. Users should note that in general, 
reverse transcriptase PCR technologies may have higher sensitivities than isothermal 
assays (286–289).
Benefits of near-patient NAAT assays include ease of use and reduced process steps 
compared to those with older molecular assays, software that allows for easier result 
interpretation, and closed systems to reduce contamination (286–289). Drawbacks of 
near-patient NAAT assays include the potential to cause unforeseen strain on the 
laboratory (e.g., for confirmatory testing and quality assurance program support), the 
impact on resource utilization outside central laboratories, and the limited scope of 
specimen types that can be used (290–292).
A recent review of POC testing, including NAAT, identifies several barriers to 
understanding the benefits of point-of-care testing for respiratory viruses (237). Imple-
mentation of rapid nucleic acid testing could be associated with decreases in number 
of hospital admissions, length of stay, emergency department length of stay, duration
of antimicrobial use, droplet contact days, total isolation days, and receipt of antibiotics 
(238–241).
Appropriate Test Utilization in the Era of Molecular Testing
Respiratory virus testing algorithms vary between health care institutions. Re-
sources, types of laboratory facilities, and different patient populations (to name a 
few) may all play a role in the testing algorithm chosen. Choosing Wisely is a 
campaign started in 2012 that focuses on initiating discussions with both the 
patient and physicians about unnecessary procedures, treatments, and tests (293). 
This section focuses on Choosing Wisely and discusses (i) which testing options 
might be suitable to perform depending on needs, (ii) what laboratories can do 
when resources are limited, (iii) how the importance of preanalytics plays into the 
testing decision being made, and (iv) what additional considerations need to be 
discussed up front before any test or piece of equipment is adopted by the 
laboratory or health care environment. The following sections describe key steps in 
ensuring that health care workers choose respiratory tests appropriately.
Stakeholder engagement. To provide high-quality, cost-effective laboratory ser-
vices, it is imperative to understand the clinical needs of the end users when consid-
ering solutions for detection of respiratory viruses (294). Depending on the health care 
system, the laboratory may be asked to offer testing within the main laboratory or to 
play a role in determining the best test for near-patient testing. Because diagnostic 
needs vary, it is important to identify the right stakeholders at the beginning in order 
to determine appropriate process development and assay deployment.
Stakeholder discussion should include the needs of primary care providers, charac-
teristics of the patient population, clinical practice settings, required test turnaround 
time, availability and expertise of nonlaboratory staff to perform POC testing, the 
volume of testing, and potential outcomes of a new assay/process. Physician groups 
utilizing testing are broad and may include the emergency department, inpatient/ICU, 
infection prevention and control groups, and pediatric and adult outpatient services 
such as urgent care or family practice. The laboratory, along with infectious diseases 
physicians, should engage these providers to completely understand the provider/
patient need.
In order to choose wisely for respiratory virus testing, one must have a fundamental 
understanding of the needs of the organization. Early engagement with the provider 
and operational stakeholders (departmental administrators or managers overseeing 
specimen collection and/or testing) is paramount to successful test implementation. It 
is crucial for an institution to consider and understand the potential clinical and 
financial impact of a diagnostic test. Some decisions may be made based on outcome 
data in the literature or data that are internally generated (263, 295–304). Outcomes 
can include (but are not limited to) cost, TAT, infection prevention and control 
decisions, antibiotic administration, antiviral administration, inpatient LOS, rates of 
admission to the hospital, referrals, and ancillary testing (chest radiography or other 
laboratory testing) (299, 302). A positive or defined outcome not only demonstrates the 
utility of a specific test but can also be presented to administrators to support the 
proposal. Many institutions today are implementing test algorithm changes in part due 
to evidence-based medicine and outcome data.
A PubMed search for the terms “respiratory,” “virus,” “testing,” “utilization,” and 
“compliance” found no articles related to utilization and compliance for respiratory 
virus testing; however, we have identified a need for monitoring usage after imple-
menting algorithms to ensure compliance and appropriate utilization of tests by the 
ordering health care workers.
Choosing the right test. As evidenced by the diversity of institutional provider 
groups discussed above, a single solution might not work for all patient populations 
or specialties of care. In choosing wisely, regardless of the test or the ability to be 
reimbursed, the emphasis should be on what the provider will do with the result 
and how implementation will impact the clinical outcome, the quality of care given
to the patient (e.g., reduction in unnecessary antibiotic use or duration) or the 
institution (e.g., reduced length of stay [LOS] in the hospital). Because many 
laboratories are being asked to do more with less, it is incumbent on not just the 
laboratory personnel, but all health care professionals, to spend money wisely and 
show the impact of testing that is implemented. Quality of care is also improved 
when physicians understand how to best use a result from a laboratory test. In 
many electronic medical records (EMR), decision trees can be adopted to aid in 
appropriate test selection, and tests can be restricted by patient location (e.g., 
inpatient versus outpatient) to promote effective ordering habits. As fee-for-service 
models are replaced with integrated care delivery systems, test reimbursement 
becomes less of a driver for best practices for respiratory virus testing. For example, 
laboratorians should consider the importance of providing influenza A virus sub-
type data when using/considering molecular assays, as some FDA-cleared tests do 
not provide the subtype. In some settings, clinicians may not voice concerns about 
lacking subtype information. An argument against subtyping is that subtyping 
matters only when circulating subtypes have different patterns of resistance to 
antiflu drugs. In other settings, clinicians may use subtyping data to place patients 
in cohorts in health care settings with low bed-to-patient ratios.
As described above, many providers have historically relied on RADTs, culture, or 
direct fluorescent-antibody (DFA) testing for the detection of respiratory viruses. RADTs 
have still maintained their popularity because of their rapidity even though they are 
suboptimal in regard to sensitivity (209, 305). Over the last decade, the use of NAATs 
with relatively faster sample-to-answer times has replaced that of more traditional 
methods (306). Sample-to-answer methods with TATs of 1 h may be acceptable for 
hospitalized patients, or perhaps patients in the ED, but TATs exceed those required in 
outpatient setting. More recently, FDA-cleared and CLIA-waived NAATs with sensitivi-
ties and specificities comparable to those of FDA-cleared laboratory-based molecular 
tests have become available (307).
Complex multiplex PCR assays are often restricted to hospital settings and 
reserved for the most ill patients with associated comorbidities. Diagnosis of 
respiratory illness in this setting is deemed important to the physician even though 
treatment might not be available for a specific pathogen. The infection prevention 
and control needs of a health care institution may warrant the implementation of 
multiplexed testing to appropriately place patients with similar infections in cohorts 
when bed space is restricted. These multiplex assays can be further divided into 
random-access and batched testing platforms (306). Both routine and unplanned-
for laboratory needs may require the laboratorian to consider utilizing both 
batched testing and random-access test systems. Random-access platforms are 
suggested for daily use in laboratories with low to medium specimen volumes, with 
the benefit of a rapid turnaround time and simplified workflow. As test volumes 
increase, the laboratorian may reconsider test algorithms and utilize a batched 
testing platform (308). Some algorithms may improve cost-effectiveness by offering 
a less-expensive upfront singleplex assay for FLU or duplexed or triplexed assays, 
including FLU and RSV, and using multiplex panels only if the sample is negative for 
FLU; however, algorithms will vary by institution, time of year, and prevalence of 
influenza. Furthermore, algorithms should be chosen based on stakeholder engage-
ment and the individual testing needs of the patient population.
So, how is this made operational? We have provided a risk assessment flow chart in 
Fig. 2. We realize that a single approach will not be applicable to all laboratories. 
Therefore, laboratorians should work with their clinical partners and manufacturers to 
establish risk-based algorithms which can be used to determine the appropriateness of 
testing. Test ordering systems, clinical information, and patient location, as well as 
demographic identifiers, can be used to streamline the placing of specimens into 
appropriate test algorithms (e.g., no testing, testing for limited targets, or broad panel 
testing). Laboratorians should offer clinicians the opportunity to discuss cases that do
FIG 2 A risk assessment approach to determine populations most effectively served by acute respiratory virus 
testing. The decision-making model can be used to identify the level of test complexity for patient 
populations.
not fit into general risk groups (e.g., low versus high), where patients may benefit from 
specific laboratory tests.
Recent Issues Surrounding LDTs for the Diagnosis of Acute Respiratory Viral 
Infections
LDTs may find a role in the clinical laboratory under the following scenarios: where 
commercial assays are not available, when performance issues emerge with commercial 
respiratory virus assays, or when a new assay is required immediately (e.g., in the event 
of an emerging respiratory pathogen) (309). LDTs are defined as assays developed and 
performed by high-complexity laboratories (e.g., “home brew” or “in-house” assays) 
that are “intended for clinical use” (310). Draft guidance documents surrounding LDT 
use were released in 2014 by the FDA, which provide guidance for clinical laboratories, 
industry, and drug administration staff (310). As of 2016 to 2017, the FDA proposed a 
“risk-based, phased-in approach, in combination with continued exercise of enforce-
ment discretion for certain regulatory requirement and certain types of LDTs”; however, 
it is up to the individual laboratory to calculate the risk associated with the use of LDTs 
(311). These issues are not specific to the United States (312). This proposed framework
would place each LDT into a specific risk class (305), and laboratories in other countries 
may benefit from comparing how they and their U.S. colleagues perform risk assess-
ments (313).
Section Summary and Recommendations
Older methods such as rapid antigen detection techniques, DFA tests, and viral 
culture have essentially been replaced by more rapid and sensitive NAAT assays, which 
have improved the characteristics of laboratory tests for the diagnosis of acute respi-
ratory viral infections. However, the highly sensitive nature of these tests as well as the 
possibility for molecular contamination means that laboratorians need to develop 
processes and practices to prevent molecular contamination. Laboratorians should 
understand the risks and benefits of using LDTs and potential regulations restricting 
their use. Rapid POC NAATs are allowing for the rapid detection of multiple respiratory 
pathogens compared to routine laboratory NAATs. Multiplexed NAATs, including POC 
tests, now allow for rapid detection with faster turnaround times (TATs) and sensitivity 
and specificity equivalent to those of laboratory-based NAATs. Apart from patient 
management for FLU, the patient and system benefits of multiplexed NAATs require 
further study, and current study outcomes may be confounded by multiple factors. 
Laboratorians should consider strong utilization approaches when initiating supporting 
NAAT POC test and multiplexed NAAT implementation. Laboratory utilization discus-
sions should take into account the clinical utility of testing in specific patient popula-
tions. Finally, although NAATs are the primary method of detection, laboratorians 
should coordinate testing in a reference laboratory that undertakes viral culture 
techniques to allow for phenotypic influenza virus characterization and/or antiviral 
susceptibility testing as part of ongoing public health surveillance.
ANTIVIRAL AND PROPHYLACTIC AGENTS: IMPACT ON THE CLINICAL 
LABORATORY
RSV Prophylaxis and Antiviral Agents
The use of palivizumab (314) has been described above. Laboratory diagnosis of RSV 
has no direct impact on the decision-making on when to initiate palivizumab prophy-
laxis, but general laboratory testing trends may help in the determination of when the 
RSV season starts and ends in some locations (95).
Although the use of multiple agents to treat respiratory viral infections has been 
described, the number of antiviral agents with FDA approval is limited. For treatment 
of RSV infection, the only approved agent is ribavirin (in aerosolized form). The use of 
aerosolized ribavirin can pose health hazards to health care workers and is not easy to 
deliver to patients, making it a less-than-ideal treatment choice. The 2012 Report of the 
Committee on Infectious Diseases (Red Book) focuses on pediatric infections and indi-
cates that primary treatment for RSV is supportive. The Red Book does not recommend 
the routine use of ribavirin but does indicate that use may be considered in “selected 
patients with documented, potentially life-threatening RSV infections” (315). Research-
focused approaches regarding RSV mutations is not described further here; however, 
potential mutations driving resistance against palivizumab and issues with ribavirin are 
described in a recent review (215). A comprehensive review of the effectiveness of 
antivirals for these viruses is beyond the scope of this guidance document, but there 
are emerging data supporting the use of oral ribavirin in treatment of URTI and LRTI in 
stem cell transplant patients (102, 103, 316–318). As new antiviral agents for RSV (and 
other viruses) become approved, laboratorians may need to develop processes for 
systematic antiviral resistance testing and surveillance.
Treatment and Prevention of Influenza
FLU is the only respiratory virus discussed in these guidelines that currently has a 
vaccine available for prevention (315). Clinical laboratories should work with their 
public health laboratories to ensure that appropriate FLU characterization by culture 
and molecular methods occurs. Culture may still be required for phenotypic strain
typing as well as antiviral susceptibility testing as part of studies or national surveillance 
systems. These data may also help support decision-making regarding FLU vaccine 
effectiveness (41).
Currently licensed antivirals for influenza include the adamantanes, which block 
the activity of the M2 protein (active only against FLUA), and neuraminidase (NA) 
inhibitors (NAIs), which block the activity of the NAs of influenza A and B viruses. At 
the time of this publication, NAIs are the only drugs that are effective for the 
prevention or treatment for influenza. Adamantanes, which do not have activity 
against FLUBs, are no longer effective against seasonal FLUA (319). Two NA inhib-
itors, oral oseltamivir and inhaled zanamivir, are licensed in many countries. In 
addition, intravenous peramivir is licensed in Japan, China, South Korea, Canada, 
and the United States. A fourth drug of this class, long-acting inhaled laninamivir, 
is licensed in Japan. Similar to the case for M2 blocker-resistant viruses, viruses 
resistant to an NA inhibitor(s) may gain an evolutionary advantage and spread 
beyond countries employing NA inhibitor therapy. In 2007 to 2009, oseltamivir-
resistant A(H1N1) seasonal prepandemic viruses rapidly emerged and spread glob-
ally (320, 321). In contrast, influenza A H1N1 (pdm09) virus strains are almost 
universally susceptibility to oseltamivir and zanamivir (322). Continuous antiviral 
susceptibility testing of seasonal FLU viruses is imperative to identify and track the 
emergence and spread of viruses resistant to NA inhibitors and M2 blockers.
Relevance of FLU Antiviral Resistance Testing
Guidelines from the Community Network of Reference Laboratories for Human 
Influenza in Europe suggest that testing for antiviral resistance is typically indicated in 
the following instances: (i) in patients lacking virological improvement (persistent virus 
shedding after 5 days of treatment using ab NAAT that “delivers semi-quantitative 
information” [e.g., a real-time PCR with a CT value]), (ii) in patients treated with antivirals 
with severe FLU who do not clinically improve (time frame not given), (iii) in fatal cases 
where an understanding of resistance may influence prophylaxis of contacts, (iv) in 
cases of FLU developed during or after antiviral prophylaxis, and (v) in contacts of 
antiviral-treated FLU patients who developed respiratory symptoms or in contacts of 
FLU patients for whom the presence of resistant virus had been confirmed (323). One 
group that may benefit from antiviral testing is patients who shed virus for long periods 
of time and who do not improve after treatment (e.g., highly immunocompromised 
patients) (324, 325).
As molecular markers of resistance are not well established and vary depending on 
virus type/subtype and NA inhibitor, determination of antiviral resistance should be 
carried out in a reference laboratory with experience in these techniques (326). Doc-
uments created by the WHO’s Global Influenza Surveillance and Response System 
(GISRS) and the WHO Influenza Antiviral Working Group (WHO-AVWG) can assist in the 
interpretation of these results (327, 328). Other documents may be available from other 
committees which provide guidance on the use of influenza antivirals (329).
Section Summary and Recommendations
Laboratorians should identify a reference laboratory for the characterization of 
influenza and antiviral susceptibility testing. Antiviral testing is not a routine test, and 
the time required to undertake such testing limits the clinical relevance of this testing 
in most patient populations. Antiviral testing may be required for epidemiological 
studies as well as cases of failure in prophylaxis. One patient population that may 
benefit from this testing is patients who are highly immunocompromised who do not 
clinically improve following antiviral treatment and who may shed virus for an ex-
tended period of time.
CODING AND REIMBURSEMENT
This section was introduced into the guidance document following presentation of 
these guidelines in the draft from at an ASM general meeting. Current procedural
terminology (CPT) is a set of guidelines, codes, and descriptions used to elucidate and 
standardize services by health care professionals, including testing in the clinical 
laboratory. The CPT codes for microbiology and virology are established through the 
Pathology Coding Caucus (PCC) of the American Medical Association (AMA). CPT codes 
in microbiology and virology have a 5-digit identifier with a description of the target 
and procedure (e.g., 87,633, CPT code in the category “infectious agent detection by 
nucleic acid [DNA or RNA]”). New codes are published yearly. Inclusion of a code in the 
CPT manual does not imply endorsement of the test, nor does it cover insurance or 
reimbursement policies.
In general, when a new test that needs a code is available, a proposal for coding is 
presented to the PCC. Among the criteria used by the PCC to review the request are test 
methodology definition, the volume of test utilization, the medical necessity, and 
scientific publications detailing performance and outcomes studies for the new test. 
After each caucus meeting, a document entitled “CPT Editorial Summary of Panel 
Actions” is prepared, which summarizes the actions that were taken by the panel on 
each of the code applications.
Pricing/fee setting for a CPT code is the purview of the Centers for Medicare and 
Medicaid Services (CMS). Annually, the CMS holds the Clinical Laboratory Fee Schedule 
(CLFS) meeting at its headquarters in Baltimore, MD. Stakeholders present the code(s)
(as established by the PCC) and a proposed reimbursement amount (based on an 
existing rate or as a recommend new rate based on a comprehensive cost analysis). The 
CMS Advisory Panel on Clinical Laboratory Diagnostic Tests functions to establish 
payment rates based on crosswalking or gapfilling and establishes factors used for 
determining coverage and payment processes (330).
Per the CMS (331), crosswalking occurs when a new test (or substantially revised 
test) is determined to be similar to multiple existing test codes, portions of an existing 
test code, or an existing test code. Gapfilling occurs when there is no existing compa-
rable test available (331).
As of 2017, reimbursement compliance is a system in place to ensure that the 
testing being performed is medically relevant for the clinical situation. Here, appropri-
ate testing for specific clinical conditions and clinical outcomes is critical. The issue of 
medical relevance has been raised in virology recently in regard to multiplex respiratory 
virus and gastrointestinal panels. In brief, CPT code 87,633, defined as respiratory virus 
(e.g., ADV, FLU, CoV, hMPV, PIV, or RV), includes multiple NAAT reactions, and multiplex 
NAAT panels with target numbers (including types or subtypes) ranging from 12 to 25 
targets. The medical necessity and reimbursement for these multiplex assays have been 
challenged, and Medicare and Medicare administrative contractor (MACs) alerted pro-
viders that a “broad-net” or “one-size-fits-all” panel contributes to test overutilization 
and increased health care costs without specific benefit to a given patient. They assert 
that testing should be limited to organisms with the greatest likelihood of occurrence 
in a given patient population and, if results are negative, to provide reflexive testing to 
more “exotic” organisms.
A consortium of clinical organizations whose members represent testing laborato-
ries has submitted comments directly to MACs, recommending a thorough review of 
this issue. At the time of this writing, only a partial resolution has occurred (as per verbal 
communication by one of the authors).
Payment rates continue to be under scrutiny and have been discussed during 
implementation of the Protecting Access to Medicare Act (PAMA). This statute calls 
for a market-based fee schedule based on a weighted median of individual private 
payor test reimbursements reported by “applicable laboratories,” which by specific 
requirements excluded hospital laboratories. Applicable laboratories included 45%
of all commercial laboratories and 5% of physician office laboratories. As such, the 
data for reimbursement are heavily weighted by discounted pricing by large 
commercial entities to major payors (MACs). Beginning in January 2018, the inten-
tion was for price reductions to be implemented at 10% in each of the next 3 years, 
followed by a 15% reduction for the following 3 years, until the established
weighted median price is hit. These new fees were to be applied to all who are paid 
using the CLFS. Of note, concerned organizations and individuals have contacted 
CMS about the detrimental effect of the act and the predicted closure of many 
laboratories and the impact on patient care. The status of these new fees was in 
question as of January 2018 (332).
Section Summary and Recommendations
Laboratorians should be aware of reimbursements for existing and new diagnostics 
for respiratory in their locations.
CONCLUSIONS
This is the most recent update of ASM practice guidelines for clinical microbi-
ology, addressing changes to acute respiratory viral infection diagnostics since the 
previous document, which was published in 1986. Since that time, laboratory 
practices as well as clinical practices have changed extensively. The guidelines were 
developed for the laboratory diagnosis of viruses causing acute respiratory illness, 
with technologies ranging from low- to high-complexity testing. Respiratory virus 
testing may be considered if a diagnosis has impact on patient management, 
especially when FLU treatment decisions are based on test results or in immuno-
compromised patients. In general, testing immunocompetent patients will not 
impact patient management. However, testing may be undertaken for surveillance 
in sentinel labs, to guide infection control decisions/practices, or when highly 
pathogenic emerging pathogens are suspected.
The landscape of respiratory virus testing has significantly changed in the last 
30 years. The decreased use of older technologies such as viral culture and direct 
antigen detection represents a significant programmatic change in the diagnosis of 
respiratory viruses. Many front-line clinical laboratories have completely phased out 
viral culture, and testing such as strain typing and antiviral resistance testing is 
generally limited to reference laboratories. Molecular techniques are now the preferred 
diagnostic approaches for the detection of acute respiratory viruses and are more 
amenable to automation and high-throughput workflows. Good molecular laboratory 
practices and quality assurance programs are keys to preventing laboratory contami-
nation. The decreasing complexity of platforms used for molecular testing has ex-
panded the geographic capacity of these assays, which can now be placed closer to 
patients as POC tests, while newer technologies have made multitarget panels widely 
available. For novel and emerging respiratory viruses, laboratory-developed tests will 
still be required to compensate for testing gaps that often need to be filled quickly. 
With all the advances in technology, however, effective communication between 
clinicians and the laboratory is still essential to quickly identify highly transmissible 
emerging pathogens and reduce health care worker exposure. Laboratorians should 
work closely within their teams as well as with other clinicians and public health 
practitioners to ensure that health systems are prepared for the inevitable emergence 
of new respiratory viral pathogens.
Implementation of clinically relevant testing algorithms can ensure optimized patient 
care and improve laboratory resource management. Particularly, strong preanalytical 
screening approaches can facilitate appropriate specimen collection and direct providers to 
correctly order diagnostic tests as needed. Laboratorians should ensure that they continue 
to work with their public health reference laboratory colleagues to align processes to 
enable continued virus characterization and antiviral resistance testing.
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